



Research paper

Trans-lesional fractional flow reserve gradient as derived from coronary CT improves patient management: ADVANCE registry[☆]

Hideobu Takagi^{a,b,c}, Jonathon A. Leipsic^{a,*}, Noah McNamara^a, Isabella Martin^a, Timothy A. Fairbairn^d, Takashi Akasaka^e, Bjarne L. Nørgaard^f, Daniel S. Berman^g, Kavitha Chinnaiyan^h, Lynne M. Hurwitz-Koweekⁱ, Gianluca Pontone^j, Tomohiro Kawasaki^k, Niels Peter Rønnow Sand^l, Jesper M. Jensen^f, Tetsuya Amano^m, Michael Poonⁿ, Kristian A. Øvrehus^o, Jeroen Sonck^{p,q}, Mark G. Rabbat^r, Sarah Mullen^s, Bernard De Bruyne^{p,t}, Campbell Rogers^s, Hitoshi Matsuo^u, Jeroen J. Bax^v, Pamela S. Douglasⁱ, Manesh R. Patelⁱ, Koen Nieman^w, Abdul Rahman Ihdayahid^{a,x}

^a Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada

^b Department of Radiology, Iwate Medical University Hospital, Iwate, Japan

^c Department of Diagnostic Radiology, Tohoku University Hospital, Miyagi, Japan

^d Department of Cardiology, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, UK

^e Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan

^f Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark

^g Division of Nuclear Imaging, Department of Imaging, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

^h Division of Cardiology, Beaumont Academic Heart and Vascular Group, Royal Oak, MI, USA

ⁱ Division of Cardiology, Department of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA

^j Centro Cardiologico Monzino, IRCCS, Milan, Italy

^k Cardiovascular Center, Shin Koga Hospital, Fukuoka, Japan

^l Cardiac Research Unit, Institute of Regional Health Research, University Hospital of Southern DK, Esbjerg and University of Southern DK, Denmark

^m Department of Cardiology, Aichi Medical University, Aichi, Japan

ⁿ Department of Noninvasive Cardiac Imaging, Northwell Health, New York, NY, USA

^o Department of Cardiology, Odense University Hospital, Denmark

^p Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium

^q Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy

^r Division of Cardiology, Loyola University Chicago, Chicago, IL, USA

^s HeartFlow Inc., Redwood City, CA, USA

^t Department of Cardiology, University Hospital of Lausanne, Lausanne, CH, USA

^u Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan

^v Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands

^w Department of Cardiovascular Medicine and Radiology, Stanford University, Stanford, CA, USA

^x Department of Cardiology, Fiona Stanley Hospital, Harry Perkins Institute of Medical Research, University of Western Australia, Perth, Australia

ARTICLE INFO

Keywords:

Coronary artery disease (CAD)

Fractional flow reserve (FFR)

Coronary computed tomography angiography (CCTA)

Fractional flow reserve derived from coronary computed tomography (FFR_{CT})

ABSTRACT

Background: The role of change in fractional flow reserve derived from CT (FFR_{CT}) across coronary stenoses (ΔFFR_{CT}) in guiding downstream testing in patients with stable coronary artery disease (CAD) is unknown.

Objectives: To investigate the incremental value of ΔFFR_{CT} in predicting early revascularization and improving efficiency of catheter laboratory utilization.

Materials: Patients with CAD on coronary CT angiography (CCTA) were enrolled in an international multicenter registry. Stenosis severity was assessed as per CAD-Reporting and Data System (CAD-RADS), and lesion-specific FFR_{CT} was measured 2 cm distal to stenosis. ΔFFR_{CT} was manually measured as the difference of FFR_{CT} across visible stenosis.

[☆] Present address: Department of Radiology, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada.

* Corresponding author. Department of Radiology, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada.

E-mail address: jleipsic@providencehealth.bc.ca (J.A. Leipsic).

<https://doi.org/10.1016/j.jcct.2021.08.003>

Received 17 July 2021; Accepted 30 August 2021

Available online 2 September 2021

1934-5925/© 2021 The Authors. Published by Elsevier Inc. on behalf of Society of Cardiovascular Computed Tomography. This is an open access article under the CC

BY license (<http://creativecommons.org/licenses/by/4.0/>).

Results: Of 4730 patients (66 ± 10 years; 34% female), 42.7% underwent ICA and 24.7% underwent early revascularization. $\Delta\text{FFR}_{\text{CT}}$ remained an independent predictor for early revascularization (odds ratio per 0.05 increase [95% confidence interval], 1.31 [1.26–1.35]; $p < 0.001$) after adjusting for risk factors, stenosis features, and lesion-specific FFR_{CT} . Among the 3 models (*model 1*: risk factors + stenosis type and location + CAD-RADS; *model 2*: model 1 + FFR_{CT} ; *model 3*: model 2 + $\Delta\text{FFR}_{\text{CT}}$), model 3 improved discrimination compared to model 2 (area under the curve, 0.87 [0.86–0.88] vs 0.85 [0.84–0.86]; $p < 0.001$), with the greatest incremental value for FFR_{CT} 0.71–0.80. $\Delta\text{FFR}_{\text{CT}}$ of 0.13 was the optimal cut-off as determined by the Youden index. In patients with CAD-RADS ≥ 3 and lesion-specific $\text{FFR}_{\text{CT}} \leq 0.8$, a diagnostic strategy incorporating $\Delta\text{FFR}_{\text{CT}} > 0.13$, would potentially reduce ICA by 32.2% (1638–1110, $p < 0.001$) and improve the revascularization to ICA ratio from 65.2% to 73.1%.

Conclusions: $\Delta\text{FFR}_{\text{CT}}$ improves the discrimination of patients who underwent early revascularization compared to a standard diagnostic strategy of CCTA with FFR_{CT} , particularly for those with FFR_{CT} 0.71–0.80. $\Delta\text{FFR}_{\text{CT}}$ has the potential to aid decision-making for ICA referral and improve efficiency of catheter laboratory utilization.

Abbreviations

ADVANCE	assessing diagnostic value of non-invasive FFR_{CT} in coronary care
AUC	area under the receiver operating characteristic curve
CABG	coronary artery bypass grafting
CAD	coronary artery disease
CAD-RADS	Coronary Artery Disease - Reporting and Data System
CCTA	coronary computed tomography angiographZ
FFR	fractional flow reserve
FFR_{CT}	fractional flow reserve derived from computed tomography
ICA	Invasive coronary angiography; PCI = percutaneous coronary intervention

1. Introduction

Physiological assessment with fractional flow reserve (FFR) guides the revascularization in patients with stable coronary artery disease (CAD).^{1,2} The application of computational fluid dynamics to a standard coronary computed tomography angiography (CCTA) enables non-invasive FFR measurement (FFR_{CT}) without additional imaging, medications, radiation exposure, or hospital visits.³ Numerous studies have demonstrated the diagnostic performance,^{4,5} prognostic value,^{6,7} and clinical utility of FFR_{CT} in real-world practice.^{7–9} FFR_{CT} is derived along the epicardial coronary tree. This allows for a flexible and lesion-specific approach that goes beyond the standard assessment which focuses on whether vessel specific FFR_{CT} falls below a specific cut-off. The change in FFR_{CT} values across a stenosis ($\Delta\text{FFR}_{\text{CT}}$) represents an estimate of lesion-specific pressure loss and have been shown to discriminate a more focal phenotype of physiology and identify high risk plaques.^{10,11}

The ADVANCE (Assessing Diagnostic Value of Non-invasive FFR_{CT} in Coronary Care) registry (NCT02499679) is an international multicenter prospective registry that enrolled stable patients with CAD who were investigated with CCTA and FFR_{CT} .^{7,8} More than half of patients who underwent ICA in gray-zone FFR_{CT} value did not receive subsequent revascularization in the ADVANCE registry. There could be space to utilize FFR_{CT} beyond the standard measurement of FFR_{CT} in terms of catheter laboratory utilization. In this analysis, we hypothesized that $\Delta\text{FFR}_{\text{CT}}$ would improve the identification of those who required early revascularization and investigated the incremental value of $\Delta\text{FFR}_{\text{CT}}$ at improving the efficiency of downstream invasive testing as assessed by the revascularization to invasive coronary angiography (ICA) ratio.

2. Materials and methods

2.1. Study design and population

The design and outcomes of the ADVANCE registry have been described previously.^{7,8} Patients being investigated for clinically suspected CAD with documented $>30\%$ stenosis on CCTA were prospectively enrolled at 38 sites in Europe, Japan, and North America from July 2015, to October 2017. Exclusion criteria were poor CCTA image quality, life expectancy <1 -year, or an inability to comply with follow-up requirements. The decision to request an FFR_{CT} analysis was independently determined by the clinician reporting the CCTA. All patients provided written informed consent following institutional review board review and approval. In this secondary analysis, patients not referred for FFR_{CT} analysis or in whom FFR_{CT} was unanalyzable or unavailable were excluded (Supplemental Figure 1).

2.2. CCTA acquisition and interpretation

CCTA was performed as per local practice and international guidelines.^{12,13} The sites investigators graded coronary stenosis severity as normal, 0%–29%, 30%–49%, 50%–69%, 70%–90%, $>90\%$, occluded (100%). For this sub-analysis, the per-patient anatomical severity was classified according to the Coronary Artery Disease – Reporting and Data System (CAD-RADS™) (Supplemental Table 1).¹⁴ This evaluation did not include high-risk plaque findings in this study.

2.3. FFR_{CT} analysis and measurements

The analysis was blindly performed at HeartFlow (Redwood, CA, United States). For all patients, 3-dimensional anatomic models of epicardial coronary arteries and aortic root were generated from CCTA images.

In accordance with the expert consensus for interpretation of FFR_{CT} ,¹⁵ we obtained both lesion-specific FFR_{CT} and $\Delta\text{FFR}_{\text{CT}}$ for each coronary vessel using the patient-specific 3-dimensional FFR_{CT} model. A central core laboratory (Duke Clinical Research Institute, Durham, NC, United States) blinded to clinical information reviewed all FFR_{CT} . Lesion-specific FFR_{CT} was measured at 2 cm distal to stenosis for each coronary artery.¹⁵ An FFR_{CT} of ≤ 0.8 was defined as a positive value. Additional analyses, blinded to clinical information, were performed in our core laboratory (St. Paul's Hospital, Vancouver, BC, Canada), where we reviewed all FFR_{CT} models and measured $\Delta\text{FFR}_{\text{CT}}$. The $\Delta\text{FFR}_{\text{CT}}$ represents the change in FFR_{CT} across a stenosis and was measured as the difference in FFR_{CT} values proximal and distal to a stenosis. The proximal and distal reference points were both manually identified at the most adjacent points to visible stenosis on the 3-dimensional FFR_{CT} model (Fig. 1).¹⁶ The distance between the proximal and distal $\Delta\text{FFR}_{\text{CT}}$ reference points was visually assessed to characterize the stenosis type (Fig. 1D–F):

- Focal – length <1 coronary segment, assuming <39 mm

- Diffuse – length >1 segment, assuming ≥ 40 mm

In a case with diffuse stenosis, after placing proximal reference at the most adjacent to the visible stenosis, carefully looked along downstream coronary and placed the distal reference at the point with visually normal diameter being the most adjacent to stenosis. The reproducibility of $\Delta\text{FFR}_{\text{CT}}$ was excellent (Supplemental document). The lesion location was determined according to the Society of Cardiovascular Computed Tomography guidelines.¹² Per-patient lesion-specific FFR_{CT} was recorded as the lowest lesion-specific FFR_{CT} in major epicardial coronary arteries, and $\Delta\text{FFR}_{\text{CT}}$ associated with the minimum lesion-specific FFR_{CT} was deemed per-patient $\Delta\text{FFR}_{\text{CT}}$.

2.4. Patient management and clinical end points

The site investigator and the institution's heart team reviewed clinical data and interpreted all available diagnostic tests, including CCTA and FFR_{CT} . The clinical management decisions including revascularization or medical therapy, entirely rested with the site physician and heart team.¹⁷ Early revascularization was defined as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) performed within 90 days after enrollment.^{8,17} Patients who did not undergo early revascularization were deemed to have undergone medical therapy alone.

The primary endpoint of this study was the early revascularization.

The secondary endpoints were the number of ICA and the ratio of early revascularization.

2.5. Statistical analysis

Descriptive statistics were presented as mean \pm standard deviation for continuous variables and raw number (percentages) for categorical variables. Independent variables were compared using unpaired t or Fisher's exact test as appropriate. Multivariable logistic regression analysis was conducted to assess the association between $\Delta\text{FFR}_{\text{CT}}$ and early revascularization. The multivariable adjustment was performed for clinical risk factors (age, sex, symptom status, hypertension, diabetes, hyperlipidemia, and current smoking), CAD-RADS, lesion-specific FFR_{CT} , lesion location, and stenosis type, and the interaction between lesion-specific FFR_{CT} and $\Delta\text{FFR}_{\text{CT}}$. Heterogeneity of the relationship between $\Delta\text{FFR}_{\text{CT}}$ and early revascularization was assessed according to subgroups including symptom, CAD-RADS, lesion-specific FFR_{CT} , stenosis location, and stenosis type. Three models were created to assess the incremental value of $\Delta\text{FFR}_{\text{CT}}$ to a standard CCTA with FFR_{CT} strategy: *model 1*, risk factors + CAD-RADS + stenosis type and location; *model 2*, *model 1* + lesion-specific FFR_{CT} ; and *model 3*, *model 2* + $\Delta\text{FFR}_{\text{CT}}$. The area under the curve (AUC) was compared using DeLong's test.¹⁸ Heterogeneity of the incremental value was assessed according to CAD-RADS and lesion-specific FFR_{CT} severity. A 2-sided *p*-value of <0.05 was considered




Fig. 1. Methodology for determining $\Delta\text{FFR}_{\text{CT}}$ and stenosis type. First the presence of and extent of stenosis is visually determined by analysing the 3-dimensional (3D) model in multiple projections. Proximal and distal reference points are then marked on the 3D model at regions immediately adjacent to the stenosis at regions which appear free of luminal stenosis (B and C). The $\Delta\text{FFR}_{\text{CT}}$ was defined as the difference of FFR_{CT} values between these two points. The stenosis type for each $\Delta\text{FFR}_{\text{CT}}$ measurement was visually assessed as *focal* or *diffuse*, based on lesion length visually assessed on the 3D coronary model as follows (D and E).

statistically significant in all tests. Computation was performed using JMP PRO version 14 (SAS Institute Inc., Cary, NC, USA) or R version 4.1 (R Foundation, Vienna, Austria).

2.6. Simulation of efficacy of ICA referral

We conducted an ICA referral simulation to assess the impact of $\Delta\text{FFR}_{\text{CT}}$ on the efficiency of catheter laboratory utilization. We randomly selected 2839 (60.0%) patients for determining the cut-off value of $\Delta\text{FFR}_{\text{CT}}$ according to the Youden index and validated the cut-off value with the remaining patients. This analysis allows for the greatest extent of confirmation possible without a separate cohort. Subsequently, we simulated referral for ICA according to three potential strategies: *Anatomical*, ICA referral for patients with CAD-RADS ≥ 3 ; *Lesion-specific FFR_{CT}*, CAD-RADS ≥ 3 and lesion-specific $\text{FFR}_{\text{CT}} \leq 0.80$; and *$\Delta\text{FFR}_{\text{CT}}$* , CAD-RADS ≥ 3 , lesion-specific $\text{FFR}_{\text{CT}} \leq 0.80$, and $\Delta\text{FFR}_{\text{CT}} >$ cut-off value. To account for other clinical factors related to a decision for early revascularization, we applied this simulation to patients who underwent ICA, meaning that more likely to undergoing ICA. For each of these strategies, the potential impact of $\Delta\text{FFR}_{\text{CT}}$ at reducing the number of ICA and improving the ratio of subsequent revascularization was assessed.

3. Results

3.1. Patient characteristics

Of the 5083 patients enrolled in the registry, FFR_{CT} analysis was requested in 4893 (96.2%). FFR_{CT} analysis was feasible in 4737 (93.2%) and accessible for this sub-analysis in 4730 (93.1%) (Supplemental Figure 1). A total of 2092 (42.7%) patients underwent ICA within 90 days, with 1168 (24.7%) patients requiring early revascularization (PCI: 1017 [87.1%]; CABG 151 [22.9%]). Patients who underwent revascularization were more likely to be male and to have typical angina, hypertension, diabetes mellitus, hyperlipidemia, and active smoking (Table 1).

Table 1
Patient characteristics.

Variables	Total (n = 4730)	Medication (n = 3562)	Revascularization (n = 1168)	P-value
Demographics				
Age, yr	66 ± 10	66 ± 10	66 ± 10	0.678
Female sex, n (%)	1602 (34%)	1285 (36%)	317 (27%)	<0.001
Body mass index, kg/m ²	26 ± 5	26 ± 5	26 ± 4	0.446
Previous coronary stenting, n (%)	159 (4%)	126 (4%)	33 (3%)	0.389
Angina status, n (%)				<0.001
Typical	1024 (22%)	586 (17%)	438 (38%)	
Atypical	1724 (36%)	1381 (39%)	343 (29%)	
Dyspnea	472 (10%)	375 (11%)	97 (8%)	
Non-cardia Pain	296 (6%)	245 (7%)	51 (4%)	
None	1162 (25%)	928 (26%)	234 (20%)	
Risk factors				
Hypertension, n (%)	2831 (60%)	2091 (59%)	740 (63%)	0.017
Diabetes mellitus, n (%)	1034 (22%)	719 (20%)	315 (27%)	<0.001
Hyperlipidemia, n (%)	2749 (58%)	1999 (56%)	750 (64%)	<0.001
Current smoker, n (%)	797 (17%)	560 (16%)	237 (20%)	<0.001

Note. — data are presented as mean ± standard deviation or percentages with raw data in parenthesis. Contentious and categorical variables were compared among groups using the unpaired t-test and Fisher's exact test.

3.2. Relationship of CAD severity with actual treatment

Table 2 summarizes anatomical and physiological CAD characteristics. Patients with early revascularization showed higher CAD-RADS grading, as well lower lesion-specific FFR_{CT} and larger $\Delta\text{FFR}_{\text{CT}}$. A larger $\Delta\text{FFR}_{\text{CT}}$ was observed with increasing stenosis severity (Supplemental Figure 2A); further, a larger $\Delta\text{FFR}_{\text{CT}}$ was observed in patients with early revascularization across each anatomical severity (Fig. 2A). A larger $\Delta\text{FFR}_{\text{CT}}$ was associated with lower lesion-specific FFR_{CT} (Supplemental Figure 2B); furthermore, a larger $\Delta\text{FFR}_{\text{CT}}$ was observed in patients requiring early revascularization across each group stratified by 0.05 increments in lesion-specific FFR_{CT} (Fig. 2B).

Early revascularization was associated with a larger $\Delta\text{FFR}_{\text{CT}}$ as compared to patients treated medically (0.24 ± 0.15 vs. 0.10 ± 0.09 ; $p < 0.001$). With increasing $\Delta\text{FFR}_{\text{CT}}$, patients were more likely to undergo ICA and revascularization and were associated with an increase in the revascularization to ICA ratio (Fig. 3). The revascularization rate in patients with CAD-RADS 3 and ≥ 4 was 15.6% (276/1773) and 50.6% (858/1696), respectively. Patients with a lesion-specific FFR_{CT} of >0.80 , 0.71–0.80, and ≤ 0.70 underwent revascularization at a rate of 4.4% (70/1588), 17.0% (275/1615), and 53.9% (823/1527), respectively.

3.3. $\Delta\text{FFR}_{\text{CT}}$ as an independent predictor for early revascularization

$\Delta\text{FFR}_{\text{CT}}$ remained an independent predictor for early revascularization after adjusting for age, sex, hypertension, hyperlipidemia, diabetes mellitus, angina status, CAD-RADS, stenosis type and location, and FFR_{CT}

Table 2
Coronary artery disease extent.

	Total (n = 4730)	Medications (n = 3562)	Revascularization (n = 1168)	P-value
Anatomical severity				
CAD-RADS, n (%)				<0.001
≤ 2	1261 (27%)	1227 (34%)	34 (3%)	
3	1773 (38%)	1497 (42%)	276 (24%)	
≥ 4	1696 (36%)	838 (24%)	858 (73%)	
3-vessel $>70\%$ disease	136 (3%)	44 (1%)	92 (8%)	<0.001
Left main $\geq 50\%$ disease	163 (3%)	85 (2%)	78 (7%)	<0.001
FFR_{CT} findings				
Minimum lesion-specific FFR_{CT}^a	0.74 ± 0.12	0.77 ± 0.10	0.63 ± 0.11	<0.001
Minimum lesion-specific FFR_{CT} , n (%)				<0.001
>0.80	1588 (34%)	1518 (43%)	70 (6%)	
0.71–0.80	1615 (34%)	1340 (38%)	275 (24%)	
≤ 0.70	1527 (32%)	704 (19%)	823 (70%)	
$\Delta\text{FFR}_{\text{CT}}^a$	0.13 ± 0.12	0.10 ± 0.09	0.24 ± 0.15	<0.001
Lesion location				
Left main	798 (17%)	669 (19%)	129 (11%)	
Proximal	1618 (34%)	1166 (32%)	452 (39%)	
Mid	1430 (30%)	1033 (29%)	397 (34%)	
Distal	587 (12%)	460 (13%)	127 (11%)	
Branch	297 (6%)	234 (7%)	63 (5%)	
Stenosis type				
Focal	4260 (90%)	3271 (92%)	989 (85%)	
Diffuse	470 (10%)	291 (8%)	179 (15%)	

Note. — data are percentages, with raw data in parenthesis, otherwise noted. Contentious and categorical variables were compared among groups using the unpaired t-test and Fisher's exact test. CAD-RADS = coronary artery disease reporting ad data system.

^a Data are mean ± standard deviation.




Fig. 2. Relationship of $\Delta\text{FFR}_{\text{CT}}$ with CAD-RADS (A) and lesion-specific FFR_{CT} (B). $\Delta\text{FFR}_{\text{CT}}$ was compared between patients with vs. without early revascularization in CAD-RADS (A) and FFR_{CT} category (B).




Fig. 3. Relationship of $\Delta\text{FFR}_{\text{CT}}$ with actual treatment at 90 days (A) and ICA results (B). Panel A shows actual treatment, including medications alone, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) stratified by 0.05 $\Delta\text{FFR}_{\text{CT}}$ increments. Panel B shows the ratio of ICA with or without revascularization and the ratio of revascularization to ICA stratified by 0.05 $\Delta\text{FFR}_{\text{CT}}$ increments.

(Table 3). The adjusted odds ratio for early revascularization per 0.05-unit increase in $\Delta\text{FFR}_{\text{CT}}$ is illustrated in Fig. 4A. After adjusting for confounders, each 0.05 increase in $\Delta\text{FFR}_{\text{CT}}$ was independently associated with a greater incidence of early revascularization. Although the predictive value of $\Delta\text{FFR}_{\text{CT}}$ was demonstrated across various subgroups, there was heterogeneity: $\Delta\text{FFR}_{\text{CT}}$ was more predictive for early revascularization in patients with CAD-RADS ≤ 3 , FFR_{CT} 0.71–0.80, or focal and tubular lesions as compared to those with CAD-RADS 4, $\text{FFR}_{\text{CT}} < 0.7$, or diffuse disease, respectively (Supplemental Figure 3).

3.4. Incremental value of $\Delta\text{FFR}_{\text{CT}}$

Receiver operating characteristic curves and the AUC of 3 logistic models for early revascularization are given in Fig. 4B. Model 2 showed higher AUC compared to model 1 (0.82 [0.81–0.83] vs. 0.85 [0.84–0.86], $p < 0.001$). Model 3 showed a higher AUC compared to model 2 (0.85 [0.84–0.86] vs. 0.87 [0.86–0.88]), $p < 0.001$, indicating that $\Delta\text{FFR}_{\text{CT}}$ had incremental value to model 2 for predicting early revascularization.

The incremental value of $\Delta\text{FFR}_{\text{CT}}$ was observed across CAD-RADS severities (Supplemental Figure 4A). Heterogeneity of the incremental value was observed according to lesion-specific FFR_{CT} . AUC improvement was observed in patients with gray-zone lesion-specific FFR_{CT} of 0.71–0.80, with no difference in those with $\text{FFR}_{\text{CT}} \leq 0.70$ or $\text{FFR}_{\text{CT}} > 0.80$ (Supplemental Figure 4B).

3.5. $\Delta\text{FFR}_{\text{CT}}$ impact on catheter laboratory utilization

A $\Delta\text{FFR}_{\text{CT}}$ of 0.13 was the optimal cut-off for predicting revascularization (Supplemental Figure 5), and we applied this cut-off value to the ICA referral simulation. Actual ICA results and simulated number of ICA and the ratio of subsequent revascularization for each strategy are given in Fig. 5. Although the number of ICA was decreased and ratio of revascularization was increased as compared to actual results, the anatomical strategy demonstrated the highest referral for ICA and lowest revascularization ratio among 3 strategies. The Lesion-specific FFR_{CT} strategy demonstrated a lower number of ICA and higher

Table 3
Multivariable logistic regression analysis for revascularization at 90-day follow-up.

Predictors	OR (95% CIs)	P-value
Patient characteristics		
Age ≥65 yr.	0.83 (0.70–1.00)	0.044
Female sex	0.79 (0.65–0.95)	0.015
Hyperlipidemia	1.40 (1.17–1.68)	<0.001
Diabetes	0.98 (0.80–1.19)	0.811
Hypertension	1.00 (0.83–1.20)	0.999
Current smoker	1.07 (0.86–1.34)	0.526
Angina status (vs. asymptomatic)		
Typical	2.32 (1.83–2.94)	<0.001
Atypical	1.33 (1.06–1.67)	0.014
Non-cardiac	1.19 (0.78–1.80)	0.417
Dyspnea	1.36 (0.98–1.89)	0.067
Imaging findings		
CAD-RADS (ref. ≤2)		
3	4.28 (2.89–6.341)	<0.001
≥4	14.79 (10.04–21.79)	<0.001
FFRCT ≤0.80 (vs. distal)	2.40 (1.49–3.85)	<0.001
ΔFFRCT (per 0.05 increase)	1.47 (1.27–1.70)	<0.001
Lesion location (vs. distal)		
LM	2.09 (1.46–2.99)	<0.001
Proximal	1.81 (1.35–2.42)	<0.001
Mid	1.63 (1.21–2.18)	0.003
Branch	1.48 (0.96–2.27)	0.075
Stenosis type (vs. diffuse)		
Focal	0.82 (0.63–1.07)	0.1433

Note. — OR = odds ratio; CAD-RADS = Coronary Artery Disease - Reporting and Data System.

revascularization ratio as compared to the *anatomical* strategy. The ΔFFRCT demonstrated the lowest referrals for ICA and the highest revascularization ratio; potentially reducing ICA by 32.2% (1638–1110, $p < 0.001$), and improving the revascularization to ICA ratio from 65.2% [1068/1638] to 73.1% [811/1110] as compared to the lesion-specific FFRCT strategy (Fig. 5). Applying a ΔFFRCT strategy, the largest improvement in revascularization to ICA ratio was observed in patients with lesion-specific FFRCT between 0.71 and 0.80 (from 43.7% [275/629] to 60.3% [143/237]) as compared to a small improvement in those with an FFRCT of ≤0.70 (from 72.6% [823/1134] to 76.5% [668/873]) (Supplemental Table 2).

4. Discussion

This analysis of the ADVANCE registry investigated the utility of ΔFFRCT at predicting early revascularization and discriminating patients with higher revascularization to ICA ratio; both of which may improve efficiency of care of patients with CAD. The main findings of this investigation are as follows: 1) ΔFFRCT values represent a continuum with larger values independently associated with early revascularization, 2) ΔFFRCT demonstrated incremental value at predicting early revascularization compared to a standard strategy of CCTA with lesion-specific FFRCT, with the greatest benefit in patients with gray-zone FFRCT values between 0.71 and 0.80, and 3) incorporating ΔFFRCT in addition to standard CCTA and lesion-specific FFRCT diagnostic strategy may reduce the number of ICA and improve the ratio of subsequent revascularization.

While there is increasing evidence supporting the use of FFRCT to improve the efficiency of catheter laboratory utilization,^{19–21} the results of the ADVANCE registry highlight some of the real-world clinical challenges of interpreting FFRCT and guiding downstream decision making. In the ADVANCE registry, 72.3% of patients undergoing ICA with lesion-specific FFRCT of ≤0.80 underwent revascularization.⁸ However, several patients were recommended for medications alone even with positive lesion-specific FFRCT results (<0.80), and some underwent ICA even with negative lesion-specific FFRCT results (0.80), highlighting that there is a space for interpreting the FFRCT results beyond the lesion-specific FFRCT. In particular, among patients with lesion-specific FFRCT between 0.71 and 0.80 and who underwent ICA, 56.3% did not subsequently undergo early revascularization. The results of this sub-analysis highlight that ΔFFRCT may improve physician decision-making in identifying patients who require revascularization, particularly those with gray-zone lesion-specific FFRCT values between 0.71 and 0.80. The results of the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial demonstrated that a routine invasive approach does not provide prognostic benefit compared to medical therapy alone.²² Accordingly, there is a renewed imperative to consider the risk and benefits of the different treatment options and improve the identification of lesions that would benefit from revascularization. Given the concerns that a first-line CCTA strategy may result in over referral for ICA,²³ the




Fig. 4. Multivariable logistic regression analysis for predicting early revascularization. Panel A shows odds ratio (solid line) with 95% confidence interval (dotted line) of ΔFFRCT compared with ΔFFRCT of 0.00–0.04 after adjusting risk factors, CAD-RADS, stenosis type and location, and FFRCT. Panel B shows receiver operating characteristic curves for three logistic models for early revascularization: *model 1* = risk factors, CAD-RADS, stenosis type and location; *model 2* = *model 1* + FFRCT; and *model 3* = *model 2* + ΔFFRCT. *Model 2* demonstrated higher AUC as compared to *model 1* (AUC difference with 95% CI, 0.02 [0.02–0.03], $p < 0.001$). *Model 3* demonstrated the highest AUC and was superior to *model 1* (0.05 [0.04–0.05], $p < 0.001$) and *model 2* (0.02 [0.02–0.03], $p < 0.001$). AUC = area under the curve; CI = confidence interval.




Fig. 5. Efficiency of catheter laboratory based on a referral strategy of the 2092 patients who underwent ICA in the ADVANCE registry. Modeling was performed to simulate the efficiency of catheter laboratory utilization according to three ICA referral strategies: *anatomical* strategy based solely on anatomical findings (CAD-RADS ≥ 3), *lesion-specific FFR_{CT}* strategy that also included lesion-specific FFR_{CT} ≤ 0.80 and a Δ FFR_{CT} strategy that incorporated Δ FFR_{CT} > 0.13 in addition to CAD-RADS ≥ 3 and lesion-specific FFR_{CT} ≤ 0.80 . Shown are the number of ICA referrals with (green) or without actual revascularization (red) and the ratio of revascularization to ICA according to ICA referral strategy. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

ability of Δ FFR_{CT} to identify lesions that require revascularization and potentially improve resource utilization is highly relevant and warrants further investigation with prospective studies.

Our findings also highlight the potential value of non-invasively characterizing the physiological pattern of CAD. Standard lesion-specific FFR_{CT} is affected by coronary atherosclerosis upstream of a measurement point, and the presence of coronary plaque causes FFR_{CT} to decrease even without the obstructive disease.²⁴ In contrast to lesion-specific FFR_{CT}, Δ FFR_{CT} represents a more stenosis-specific physiological severity and is not affected by coronary plaque beyond the stenosis. Our results suggest that adding Δ FFR_{CT} to lesion-specific FFR_{CT} may inform on disease severity and physiological phenotype. Recent invasive studies have provided similar results with an invasive FFR pullback able to characterize several physiological patterns of CAD.^{11,25,26} A high Δ FFR_{CT} provides an opportunity to identify subjects with a “focal phenotype” of physiology as described by Collet et al.¹¹ Despite the clinical benefit observed with FFR-guided PCI,²⁷ one-third of patients experience suboptimal post-PCI results, associated with major adverse cardiac events.^{28,29} Therefore, there is an increasing emphasis on achieving a physiologically optimal result post-PCI. In cases with a large focal pressure gradient, PCI is more likely to achieve an ideal functional result and symptomatic benefit for the patient²⁶; on the contrary, revascularization in vessels with diffuse pressure loss is associated with limited FFR or symptomatic improvement and even potential harm.³⁰ The current approach for reading FFR_{CT} involves interpreting an FFR_{CT} value at one point on the coronary tree, typically 20–30 mm distal to a stenosis (i.e. lesion-specific FFR_{CT}).¹⁵ Although this provides insight into total pressure loss upstream of the coronary artery measurement point, this method is limited in its capacity to characterize the lesion specific physiological phenotype requiring revascularization.³¹ Our results highlight that Δ FFR_{CT} can provide clinically relevant insight into the physiological pattern of disease requiring revascularization. With the emerging use of CCTA and FFR_{CT} to guide PCI,³² Δ FFR_{CT} may provide further non-invasive guidance for optimizing revascularization strategies and outcomes.

This study has several limitations. First, the findings related to Δ FFR_{CT} are observational in nature with inherent physician bias for both ICA referral and decisions on revascularization. Second, the endpoints in this study were driven by revascularization. The optimal cut-off value for Δ FFR_{CT} was not powered to evaluate cardiac death and myocardial infarction. However, this does not undermine the opportunity for Δ FFR_{CT} to improve the efficiency of catheter laboratory utilization and adds to recent data from the EMERALD (Exploring the Mechanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and Computational Fluid Dynamics), demonstrating the prognostic utility of Δ FFR_{CT} at identifying lesions potentially at risk of future myocardial infarction.¹⁰ Third, revascularization was not guided by invasive FFR. However, the cut-off value derived from the early revascularization as a clinical endpoint was similar to one which compared invasive FFR ≤ 0.80 or not in previous study,¹⁶ which may support that the decision for early revascularization was based on coronary physiology in the ADVANCE registry. Finally, the ICA referral simulation did not take into account symptoms and risk factors. The decision to revascularize is multi-factorial, and stenosis and FFR_{CT} are just one part of many factors taken into consideration in the decision making process. Also, the estimates were theoretical, not observed ones. Therefore, further study is warranted. We applied the simulation to patients who underwent ICA to affect clinical factors other than stenosis and FFR_{CT} severity. However, these confounding might not be fully adjusted.

5. Conclusions

In this analysis of the ADVANCE registry, Δ FFR_{CT} improves the identification of patients who required early revascularization compared to a standard diagnostic strategy with CCTA and lesion-specific FFR_{CT}, with the greatest incremental benefit in patients with gray-zone FFR_{CT} values between 0.71 and 0.80. Applying a criterion of Δ FFR_{CT} to ICA referral, efficiency of resource utilization may be improved. Prospective validation of these findings will be important to translate these findings into broader practice. Appendix A. Supplementary data.

Declaration of competing interest

This study was supported by HeartFlow, Inc., Redwood City, California, via individual Clinical Study Agreements with each enrolling institution and with the Duke Clinical Research Institute (DCRI) for Core Laboratory activities and Clinical Event Committee adjudication of adverse events. Dr. Leipsic receives institutional grants to provide core lab services to Edwards Life Sciences, Medtronic and is a consultant to Circle CVI and HeartFlow. Dr. Fairbairn is on the Speakers Bureau for HeartFlow. Dr. Nørgaard has received unrestricted institutional research grants from Siemens and HeartFlow. Dr. Berman has received unrestricted research support from HeartFlow. Dr. Chinnaiyan has received institutional grants from HeartFlow. Dr. Hurwitz-Koweek is on the Speakers Bureau for HeartFlow; and has unrestricted grant funding from Siemens and HeartFlow. Dr. Pontone is a consultant for GE Healthcare; and has research grants from GE Healthcare and HeartFlow. Dr. Rabbat has received institutional grants from HeartFlow. Dr. Mullen is an employee of HeartFlow. Dr. Rogers is an employee of and has equity in HeartFlow. Dr. Bax has received unrestricted research grants from Edwards Lifescience, Medtronic, Boston Scientific, Biotronik, and GE Healthcare; and is on the Speakers Bureau with Abbott. Dr. Douglas receives an institutional research grant from HeartFlow. Dr. Patel has received grants from HeartFlow, Jansen, Bayer, AstraZeneca, and NHLBI; and has served as a consultant for Jansen, Bayer, AstraZeneca, Genzyme, and Merck. Dr. Nieman reports institutional research support from Siemens Healthineers, Bayer, HeartFlow Inc. and is a consultant to Siemens Medical Solutions USA. Dr. Ihdahid is supported by the National Health and Medical Research Council of Australia and National Heart Foundation Scholarships; and has received honoraria from Canon Medical and Boston Scientific. All other authors have reported that they

have no relationships relevant to the contents of this paper to disclose.

Acknowledgments

The authors would like to thank Ms. Whitney Huey and Ms. Amy Flynt for their contribution towards data collection and analysis.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jcct.2021.08.003>.

Funding

This study was supported by HeartFlow, Inc., Redwood City, CA, USA, via individual Clinical Study Agreements with each enrolling institution and with the Duke Clinical Research Institute (DCRI) for Core Laboratory activities and Clinical Event Committee adjudication of adverse events.

References

- Fihn SD, Gardin JM, Abrams J, et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons, 2012 *Circulation*. 2012;126(25):e354–e471. <https://doi.org/10.1161/CIR.0b013e318277d6a0>.
- Neumann F-J, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*. 2018;40(2):87–165. <https://doi.org/10.1093/eurheartj/ehy394>, 2019.
- Taylor CA, Fonte TA, Min JK. Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve. *J Am Coll Cardiol*. 2013;61(22):2233–2241. <https://doi.org/10.1016/j.jacc.2012.11.083>.
- Nørgaard BL, Leipsic J, Gaur S, et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease. *J Am Coll Cardiol*. 2014;63(12):1145–1155. <https://doi.org/10.1016/j.jacc.2013.11.043>.
- Drissen RS, Danad I, Stuijzand WJ, et al. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. *J Am Coll Cardiol*. 2019;73(2):161–173. <https://doi.org/10.1016/j.jacc.2018.10.056>.
- Ihdayhid AR, Nørgaard BL, Leipsic J, et al. Prognostic value and risk continuum of noninvasive fractional flow reserve derived from coronary CT angiography. *Radiology*. 2019. <https://doi.org/10.1148/radiol.2019182264>. Published online June 11.
- Patel MR, Nørgaard BL, Fairbairn TA, et al. 1-Year impact on medical practice and clinical outcomes of FFRCT. *JACC Cardiovasc Imaging*. 2020;13(1):97–105. <https://doi.org/10.1016/j.jcmg.2019.03.003>.
- Fairbairn TA, Nieman K, Akasaka T, et al. Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry. *Eur Heart J*. 2018; 39(41):3701–3711. <https://doi.org/10.1093/eurheartj/ehy530>.
- Nørgaard BL, Mortensen MB, Parmer E, et al. Clinical outcomes following real-world computed tomography angiography-derived fractional flow reserve testing in chronic coronary syndrome patients with calcification. *Eur Heart J - Cardiovasc Imaging*. Published online August 13, 2020;jeaa173. doi:10.1093/ehjci/jeaa173.
- Lee JM, Choi G, Koo B-K, et al. Identification of high-risk plaques destined to cause Acute coronary syndrome using coronary computed tomographic angiography and computational fluid dynamics. *JACC Cardiovasc Imaging*. 2019;12(6):1032–1043. <https://doi.org/10.1016/j.jcmg.2018.01.023>.
- Collet C, Sonck Jeroen, Vandeloort Bert, et al. Measurement of hyperemic pullback pressure gradients to characterize patterns of coronary atherosclerosis. *J Am Coll Cardiol*. 2019;74(14):13.
- Leipsic J, Abbara S, Achenbach S, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. *J Cardiovasc Comput Tomogr*. 2014; 8(5):342–358. <https://doi.org/10.1016/j.jcct.2014.07.003>.
- Abbara S, Blanke P, Maroules CD, et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: a report of the society of Cardiovascular Computed Tomography Guidelines Committee. *J Cardiovasc Comput Tomogr*. 2016;10(6):435–449. <https://doi.org/10.1016/j.jcct.2016.10.002>.
- Cury RC, Abbara S, Achenbach S, et al. CAD-RADSTM coronary artery disease – reporting and data system. An expert consensus document of the society of cardiovascular computed tomography (SCCT), the American college of Radiology (ACR) and the North American society for cardiovascular imaging (NASCI). Endorsed by the American college of cardiology. *J Cardiovasc Comput Tomogr*. 2016;10(4): 269–281. <https://doi.org/10.1016/j.jcct.2016.04.005>.
- Nørgaard BL, Fairbairn TA, Safian RD, et al. Coronary CT angiography-derived fractional flow reserve testing in patients with stable coronary artery disease: recommendations on interpretation and reporting. *Radiol Cardiothorac Imaging*. 2019; 1(5), e190050. <https://doi.org/10.1148/ryct.2019190050>.
- Takagi H, Ishikawa Y, Orii M, et al. Optimized interpretation of fractional flow reserve derived from computed tomography: comparison of three interpretation methods. *J Cardiovasc Comput Tomogr*. 2019;2(13):134–141. <https://doi.org/10.1016/j.jcct.2018.10.027>.
- Chinnaiyan KM, Akasaka T, Amano T, et al. Rationale, design and goals of the HeartFlow assessing diagnostic value of non-invasive FFRCT in Coronary Care (ADVANCE) registry. *J Cardiovasc Comput Tomogr*. 2016;11(1):62–67. <https://doi.org/10.1016/j.jcct.2016.12.002>.
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*. 1988;44(3):837–845.
- Lu MT, Ferencik M, Roberts RS, et al. Noninvasive FFR derived from coronary CT angiography. *JACC Cardiovasc Imaging*. 2017;10(11):1350–1358. <https://doi.org/10.1016/j.jcmg.2016.11.024>.
- Nørgaard BL, Terkelsen CJ, Mathiassen ON, et al. Clinical outcomes using coronary CT angiography and FFRCT-guided management of stable chest pain patients. *J Am Coll Cardiol*. Published online. August 2018. <https://doi.org/10.1016/j.jacc.2018.07.043>.
- Douglas PS, De Bruyne B, Pontone G, et al. 1-Year outcomes of FFRCT-guided care in patients with suspected coronary disease. *J Am Coll Cardiol*. 2016;68(5):435–445. <https://doi.org/10.1016/j.jacc.2016.05.057>.
- Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med*. Published online March 30, 2020: NEJMoa1915922. doi:10.1056/NEJMoa1915922.
- Foy AJ, Dhruva SS, Peterson B, Mandrola JM, Morgan DJ, Redberg RF. Coronary computed tomography angiography vs functional stress testing for patients with suspected coronary artery disease: a systematic review and meta-analysis. *JAMA Intern Med*. 2017;177(11):1623. <https://doi.org/10.1001/jamainternmed.2017.4772>.
- Doris MK, Otaki Y, Armon Y, et al. Non-invasive fractional flow reserve in vessels without severe obstructive stenosis is associated with coronary plaque burden. *J Cardiovasc Comput Tomogr*. 2018;12(5):379–384. <https://doi.org/10.1016/j.jcct.2018.05.003>.
- De Bruyne B, Hersbach F, Pijls NHJ, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but “normal” coronary angiography. *Circulation*. 2001;104(20):2401–2406. <https://doi.org/10.1161/hc4501.099316>.
- Lee SH, Shin D, Lee JM, et al. Automated algorithm using pre-intervention fractional flow reserve pullback curve to predict post-intervention physiological results. *JACC Cardiovasc Interv*. Published online October 2020:S1936879820314795. doi: 10.1016/j.jcin.2020.06.062.
- Zhang D, Lv S, Song X, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention: a meta-analysis. *Heart*. 2015;101(6):455–462. <https://doi.org/10.1136/heartjnl-2014-306578>.
- Choi KH, Lee JM, Koo B-K, et al. Prognostic implication of functional incomplete revascularization and residual functional SYNTAX score in patients with coronary artery disease. *JACC Cardiovasc Interv*. 2018;11(3):237–245. <https://doi.org/10.1016/j.jcin.2017.09.009>.
- Piroth Z, Toth GG, Tonino PAL, et al. Prognostic value of fractional flow reserve measured immediately after drug-eluting stent implantation. *Circ Cardiovasc Interv*. 2017;10(8). <https://doi.org/10.1161/CIRCINTERVENTIONS.116.005233>.
- Baranauskas A, Peace A, Kibarskis A, et al. FFR result post PCI is suboptimal in long diffuse coronary artery disease. *EuroIntervention*. 2016;12(12):1473–1480. <https://doi.org/10.4244/EIJ-D-15-00514>.
- Rønnow Sand NP, Nissen L, Winther S, et al. Prediction of coronary revascularization in stable Angina. *JACC Cardiovasc Imaging*. 2020;13(4):994–1004. <https://doi.org/10.1016/j.jcmg.2019.06.028>.
- Nagumo S, Collet C, Nørgaard BL, et al. Rationale and design of the precise percutaneous coronary intervention plan (P3) study: prospective evaluation of a virtual computed tomography-based percutaneous intervention planner. *Clin Cardiol*. Published online March. 2021;3:23551. <https://doi.org/10.1002/clc.23551>. clc.